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Abstract
Background: Spinocerebellar ataxia type 3 (SCA3) is the most common subtype among the autosomal dominant
cerebellar ataxias, a group of neurodegenerative disorders for which currently no disease-specific therapy is available.
Evidence-based options for symptomatic treatment of ataxia are also limited. Recent investigations in a heterogeneous
group of hereditary and acquired ataxias showed promising, prolonged effects of a two-week course with daily sessions
of cerebellar anodal transcranial direct current stimulation (tDCS) on ataxia severity, gait speed, and upper limb dexterity.
The aim of the SCA3-tDCS study is to further examine whether tDCS improves ataxia severity and various (cerebellar) non-
motor symptoms in a homogeneous cohort of SCA3 patients and to explore the time course of these effects.
Methods/design: An investigator-initiated, double-blind, randomized, sham-controlled, single-center trial will be
conducted. Twenty mildly to moderately affected SCA3 patients (Scale for the Assessment and Rating of Ataxia score
between 3 and 20) will be included and randomly assigned in a 1:1 ratio to either cerebellar anodal tDCS or sham
cerebellar tDCS. Patients, investigators, and outcome assessors are unaware of treatment allocation. Cerebellar tDCS (20
min, 2 mA, ramp-up and down periods of 30 s each) will be delivered over ten sessions, distributed in two groups of five
consecutive days with a two-day break in between. Outcomes are assessed after a single session of tDCS, after the tenth
stimulation (T1), and after three, six, and twelve months. The primary outcome measure is the absolute change of the
SARA score between baseline and T1. In addition, effects on a variety of other motor and neuropsychological functions in
which the cerebellum is known to be involved will be evaluated using quantitative motor tests, static posturography,
neurophysiological measurements, cognitive assessment, and questionnaires.
Discussion: The results of this study will inform us whether repeated sessions of cerebellar anodal tDCS benefit SCA3
patients and whether this form of non-invasive stimulation might be a novel therapeutic approach to consider in a
neurorehabilitation setting. Combined with two earlier controlled trials, a positive effect of the SCA3-tDCS study will
encourage implementation of this intervention and stimulate further research in other SCAs and heredodegenerative ataxias.
Trial registration: NL7321, registered October 8, 2018.
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Background
Spinocerebellar ataxia type 3 (SCA3) is the most com-
mon subtype among the autosomal dominant cerebellar
ataxias (ADCAs), a clinically and genetically heteroge-
neous group of progressive neurodegenerative disorders
[1–3]. Ataxia has been shown to be the primary and
shared driver of both motor impairment and reduced
quality of life in various SCAs [4, 5]. In addition to de-
terioration in the motor domain, specific cognitive abil-
ities tend to decline and depressive symptoms frequently
arise during disease progression [6–13].
As therapies that specifically target the underlying
molecular and cellular processes are currently not
available, SCA3 remains an untreatable condition
and clinical management focuses on trying to pro-
vide symptomatic relief. Unfortunately, evidence-
based options for symptomatic treatment of ataxia
are still limited [14]. According to the recently pub-
lished recommendations by the American Academy
of Neurology [15], the only drug with class I study
evidence of benefit in terms of improving ataxia in
SCA patients is riluzole, although it should be noted
that this particular trial did not include SCA3 pa-
tients [16]. In daily practice, training, exercise, and
other rehabilitation programs compose the main pil-
lars of intervention. These strategies might be bene-
ficial, but previous research has shown that referrals
to these facilities are inconsistent, ataxia-specific ex-
pertise in allied healthcare is limited, and guidelines
are lacking [17]. Apart from the requirement to im-
prove the organization of neurorehabilitation care,
there is an urgent medical need to find alternative –
or synergistic – ways to provide symptomatic relief
for ataxia patients.
Cerebellar transcranial direct current stimulation
(tDCS) is an increasingly used, safe, cheap, and non-
invasive tool in neuroscience that is able to modulate
cerebellar excitability [18, 19]. Computational modeling
studies have demonstrated the biophysical feasibility of
modulating cerebellar structures using tDCS with only
negligible spreading effects to neighboring regions [20,
21]. Initially, this technique has been successfully ap-
plied in healthy volunteers to investigate the neural cor-
relates of motor learning and cognitive and emotional
processes [19, 22, 23]. More recently, studies also
started to explore its therapeutic potential in a variety
of neurological conditions [24, 25]. The first promising
results of this technique in ataxia patients – significant
reduction of upper limb postural and action tremor and
dysmetria – have been described in single cases of
SCA2 and ARCA3 due to ANO10 gene mutations [26,
27]. These effects were subsequently corroborated on a
larger scale by Benussi and colleagues in a randomized,
double-blind, sham-controlled study enrolling a rather
heterogeneous group of nineteen patients with both
hereditary and acquired ataxias. Compared to the sham
condition, a single session of anodal cerebellar tDCS re-
sulted in a significant transient improvement in scores
on the Scale for the Assessment and Rating of Ataxia
(SARA), International Cooperative Ataxia Rating Scale
(ICARS), 9-hole peg test (9HPT), and 8 m walk test
(8MWT) [28]. Furthermore, a double-blind, random-
ized, sham-controlled trial by the same authors asses-
sing the efficacy of tDCS five days per week for two
consecutive weeks in a heterogeneous group of twenty
ataxia patients – five SCA2, one SCA14, two SCA38,
one Friedreich ataxia, one ataxia with oculomotor
apraxia type 2, four multiple system atrophy cerebellar
type, one fragile X-associated tremor/ataxia syndrome,
and five sporadic adult-onset ataxia of unknown eti-
ology – showed a significant improvement on all of the
abovementioned scores up to three months after stimu-
lation. This clinical amelioration was paralleled by res-
toration of the physiological inhibition of the pathways
between the cerebellum and the contralateral motor
cortex, as measured with double-coil transcranial mag-
netic stimulation (TMS) [29]. More specifically, this
study was able to achieve a SARA score reduction of al-
most three points up to three months after stimulation,
which would nearly equal the progression in SCA3 over
two years [30]. Recently, these authors published the
results of another randomized, double-blind, sham-
controlled trial in twenty ataxia patients with mixed eti-
ologies and found similar results regarding symptom-
atic ataxia improvement and return of cerebellar brain
inhibition after ten sessions of cerebello-spinal tDCS
[31]. No serious adverse events of cerebellar tDCS have
been reported in these and other studies and it is there-
fore considered a safe and tolerable method. Possible
side effects mainly include a transient itching, tingling,
or mild burning sensation underneath the electrodes.
Inspired by these promising findings, we designed the
clinically-oriented SCA3-tDCS study to investigate
whether cerebellar anodal tDCS, compared to sham
stimulation, decreases ataxia severity and a variety of
(cerebellar) non-motor symptoms in a homogeneous co-
hort of SCA3 patients and if so, what the duration of
this beneficial effect is.
Methods/design
Study design
The SCA3-tDCS study is an investigator-initiated,
double-blind, randomized (1:1), sham-controlled, single-
center trial that will take place at the Radboud Univer-
sity Medical Center, Nijmegen, the Netherlands. Cere-
bellar tDCS will be delivered during five consecutive
days for two weeks, with a two-day break in between.
Primary and secondary outcome measures (see Tables 1
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and 2) are assessed at baseline (T0 before tDCS), after a
single session of tDCS (T0 after tDCS), after the tenth
session of tDCS (T1), and after three, six, and twelve
months of follow-up (T2, T3, and T4, respectively). For
this purpose, we will use a combined approach of a stan-
dardized neurological examination, quantitative motor
tests, cognitive assessment, questionnaires, and neuro-
physiological measurements (Table 1). This combination
of tests reflects the broad range of motor, cognitive, and
affective functions the cerebellum is known to be in-
volved in, and represents recognized domains of deficit
in patients with cerebellar diseases.
The study has been registered in the Netherlands Trial
Register (NL7321) on October 8, 2018, has been ap-
proved by the local medical ethics committee (CMO re-
gion Arnhem-Nijmegen), and will be conducted in
accordance with the Declaration of Helsinki.
Objectives
The primary objective of our study is to examine whether
a two-week intervention with cerebellar anodal tDCS
could lessen ataxia severity in SCA3 patients compared to
sham stimulation. The secondary objectives are to investi-
gate if a two-week treatment with cerebellar anodal tDCS
(1) diminishes various (cerebellar) non-motor symptoms,
(2) enhances the ability of SCA3 patients to acquire condi-
tioned responses in a delay eyeblink classical conditioning
paradigm, and (3) restores cerebellar brain inhibition
pathways compared to sham stimulation. We will (4) also
determine if a single session of tDCS has a transient bene-
ficial effect on ataxia severity.
Patient population and eligibility criteria
In order to be eligible to participate in this study, a sub-
ject must meet all of the following inclusion criteria:
 Age 16 years or older.
 Proven mutation in the ATXN3 gene.
 SARA score between 3 and 20 at a recent (pre-
study) visit. The SARA score reflects ataxia severity
and ranges from 0 (no ataxia) to 40 (very severe
ataxia) [32]. We previously distinguished between
the asymptomatic, preclinical, and ataxic stage of
SCAs and proposed definitions for each of these
[33]. As about 20% of healthy controls in the SARA
validation study were found to have positive ratings
in at least one item, we defined clinically manifest
ataxia as SARA ≥ 3 and this value will therefore be
Table 1 Overview of the questionnaires, neurological tests, and kinetic and neurophysiological measurements at the various points
in time of the SCA3-tDCS study
T0
baseline
T0
after tDCS
T1
day 12
T2
3 months
T3
6 months
T4
12 months
Questionnaires
EQ-5D-5L X X X X X
PHQ-9 X X X X X
POMS 32-item X X X X X
iMCQ X X
IPAQ parts 1 and 4 X X X
FARS part II (ADL) X X X X X
Neurological examination
CCAS scale X X X X X
SARA X X X X X X
8MWT X X X X X X
9HPT X X X X X X
PATA repetition X X X X X X
INAS X X X X X
Measurements
TMS X X
Delay EBC X X
Static posturography X X X
EQ-5D-5L EuroQol 5-Dimension 5-Level, PHQ-9 Patient Health Questionnaire-9, POMS Profile of Mood States, iMCQ Institute for Medical Technology Assessment
(iMTA) Medical Consumption Questionnaire, IPAQ International Physical Activity Questionnaire; FARS Friedreich Ataxia Rating Scale, ADL Activities of Daily Living,
CCAS Cerebellar Cognitive Affective Syndrome, SARA Scale for the Assessment and Rating of Ataxia, 8MWT 8 m walk test, 9HPT 9-hole peg test, INAS Inventory of
Non-Ataxia Signs, TMS Transcranial magnetic stimulation, EBC Eyeblink conditioning
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used as lower cut-off in the current trial. Further
analysis of the results of the Benussi et al. study
suggested that improvements following cerebellar
anodal tDCS were greater in clinically less af-
fected patients [29]. This indicates that a window
of opportunity exists, probably related to the fact
that in later stages of the disease there is severe
neuronal loss and thus an absence of target cells
to channel the tDCS effects. In this regard,
Rubinsztein and Orr even speculate about a point
of no return when a certain threshold of
neurodegeneration has been exceeded and beyond
which introduction of disease-modifying treat-
ments may be futile [34]. In the current study,
we therefore deliberately do not include SCA3 pa-
tients who are already wheelchair-bound but ra-
ther aim for mildly to moderately affected
individuals, using an arbitrary SARA upper cut-off
value of 20.
Exclusion criteria are:
 Epilepsy.
 History of brain surgery.
 Metallic implants in or near the skull.
 Presence of a pacemaker.
 Significant comorbidities that interfere with
activities of daily life.
 (Suspicion of ) pregnancy.
 Severe skin disease affecting the location where the
tDCS electrodes will be placed.
Similar to the riluzole trial [16], we deliberately chose
not to exclude patients who are receiving physical ther-
apy or who are using centrally acting neurological medi-
cation, as we here plan to study the symptomatic effect
of cerebellar tDCS added to any ongoing treatment
reflecting current daily practice.
Patients will be mainly recruited from our Radboud
University Medical Center ataxia outpatient clinic. If they
are interested to participate, they will receive a detailed
description of the study by post or e-mail and have at least
seven days consideration time. In addition, the Dutch
ADCA society will help in the recruitment by placing ad-
vertisements on their website and in their newsletter. Be-
fore enrollment, patients from other centers who are
willing to participate are invited to our hospital for a pre-
study visit in which the SARA score is determined.
Table 2 Outcome measures and tests
Outcome domain Test Time point
Primary outcome measure
Cerebellar ataxia severity SARA (absolute change from baseline) T1
Secondary outcome measures
Cerebellar ataxia severity SARA (% of patients with a decrease of≥ 1.5 points) T1
Cerebellar ataxia severity SARA score and subscores T0 after tDCS, T2-T4
Gait speed 8m walk test T0 after tDCS, T1-T4
Articulation speed PATA repetition rate T0 after tDCS, T1-T4
Upper limb dexterity 9-hole peg test T0 after tDCS, T1-T4
Extracerebellar signs INAS count T1-T4
Postural sway Static posturography T0 after tDCS and T1
Quality of life EQ-5D-5L T1-T4
Depression PHQ-9 T1-T4
Mood states POMS 32-item version T1-T4
Cognition and affect CCAS scale (total score and number of ‘fails’) T1-T4
Activities of daily living FARS part II T1-T4
Medical consumption iMCQ T4
Motor learning Delay EBC (acquisition of CRs) T1
CBI Transcranial magnetic stimulation T1
tDCS-related side effects Open question T1
Correct randomization Patients’ thoughts about treatment allocation T1
SARA Scale for the Assessment and Rating of Ataxia, INAS Inventory of Non-Ataxia Signs, EQ-5D-5L EuroQol 5-Dimension 5-Level, PHQ-9 Patient Health
Questionnaire-9, POMS Profile of Mood States, CCAS Cerebellar Cognitive Affective Syndrome, FARS Friedreich Ataxia Rating Scale, iMCQ Institute for Medical
Technology Assessment (iMTA) Medical Consumption Questionnaire, EBC Eyeblink conditioning; CR Conditioned response, CBI Cerebellar brain inhibition
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Randomization and blinding
Participants fulfilling the abovementioned criteria will be
randomly assigned in a 1:1 ratio to either cerebellar an-
odal tDCS or sham cerebellar tDCS using online software
provided by Castor EDC. A protocol of permuted block
randomization with randomly selected variable block sizes
will be applied. Furthermore, in order to ensure an equal
distribution of ataxia severity in both groups, the SARA
score of a recent (pre-study) visit will be used as a stratifi-
cation variable. The randomization procedure will be con-
ducted by an independent researcher who subsequently
picks one of the 100 five-digit codes from the neuroConn
tDCS user manual that belongs to the specific tDCS mode
(real or sham stimulation). This person is otherwise not
involved in the study. The investigator applying tDCS,
other investigators, and patients thus remain unaware of
treatment allocation.
Intervention and study procedures
At the beginning of the first visit, informed consent is
obtained from each subject participating in the study
after explanation of the aims, methods, benefits, and po-
tential hazards of the study once more. Subjects can
withdraw their consent at any time and for any reason
without incurring any penalty or withholding of treat-
ment on the part of the investigators.
Questionnaires
At various points in time during the study participants
are requested to complete a number of questionnaires
(Table 1) [5]. The EuroQol 5-Dimension 5-Level (EQ-
5D-5L) is an ordinal quality of life scale that contains
five questions addressing the domains of mobility, self-
care, usual activities, pain / discomfort, and anxiety / de-
pression, each with five answer options. In the final
question, subjects rate their overall health on a visual
scale from 0 (worst imaginable health status) to 100
(best imaginable health status). The Patient Health
Questionnaire-9 (PHQ-9) is a 9-item instrument that is
used in the screening, diagnosis, and follow-up of de-
pression. Participants record how often they experienced
each of these nine symptoms in the last two weeks, ran-
ging from never (score 0) to nearly every day (score 3),
thus resulting in a total score between 0 and 27 points.
In the shortened 32-item version of the Profile of Mood
States (POMS), 32 adjectives are presented and subjects
determine to what extent (0 = not at all to 4 = very well)
each of these is applicable to their current state. In this
way, mean scores on five different mood domains can be
evaluated, namely depression, anger, tensor, fatigue, and
vigor. The institute for Medical Technology Assessment
Medical Consumption Questionnaire (iMCQ) aims to
compute the medical costs made by the participants in
the last three months due to physical and mental
complaints [35]. These costs are calculated by multiply-
ing the price per unit of care and the volume of care for
each item. As a possible confounder, the degree of phys-
ical exertion will be assessed using parts 1 and 4 of the
long version of the International Physical Activity Ques-
tionnaire [36]. These address the amount of moderate
and vigorous exercise and time spent walking in the last
seven days at work (part 1), if any, and during recre-
ation, sport, and leisure time (part 4), and will be
expressed in Metabolic Equivalent of Task (MET)-mi-
nutes per week. The number of MET-minutes per week
is computed by multiplying the energy requirements of
the type of activity – 3.3 for walking, 4.0 for moderate
exercise, and 8.0 for vigorous physical activity – with the
amount of minutes per day and the number of days per
week on which that activity is conducted. The total work
MET-minutes and leisure-time MET-minutes per week
will be summed. Finally, part II of the Friedreich Ataxia
Rating Scale (FARS) will be used to evaluate activities of
daily living. This scale includes nine items and ranges
from 0 (no assistance needed) to 36 (fully dependent).
Cognitive and affective symptoms
In the last decades it has become increasingly clear that
the cerebellum is not only involved in motor tasks, but
also plays an important role in various cognitive func-
tions, predominantly affect regulation, executive func-
tioning, spatial cognition, and linguistic processing.
Deficits in these domains in patients with focal cerebel-
lar lesions or degenerative cerebellar disorders are col-
lectively referred to as the cerebellar cognitive affective
syndrome (CCAS) [7, 11, 12, 37, 38]. Recently, Hoche et
al. selected the most sensitive tests to screen for cerebel-
lar cognitive and affective dysfunction out of a compre-
hensive standardized neuropsychological examination
and validated this 10-item bedside screening battery test,
called the CCAS/Schmahmann syndrome scale, in a new
cohort of patients with cerebellar diseases [39]. In
addition to a total raw score (0 to 120 points), the au-
thors provided cut-offs for each item, which determine
whether a participant passed or failed this test. Possible,
probable, and definite CCAS were subsequently defined
as a failure at 1, 2, or ≥ 3 items, respectively. In the
current study, we will apply this CCAS/Schmahmann
syndrome scale and examine the influence of cerebellar
tDCS on both the total raw score and the number of
failed tests.
Neurological examination and quantitative motor tests
A standardized neurological examination will be con-
ducted and includes an assessment of ataxia severity
(SARA), which will be videotaped and rated by two highly
experienced investigators who are blind to randomization
status and point in time. The Inventory of Non-Ataxia
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Signs (INAS), a clinical assessment instrument containing
30 items, will be used to determine the amount of extra-
cerebellar involvement and results in an INAS count ran-
ging from 0 (no non-ataxia signs) to 16 (very severe
extracerebellar signs) [40]. More quantitative motor tests
include two trials of the 8MWT, two trials of the 9HPT
for each hand, and two trials of the PATA repetition rate
task, which provide measures of gait speed, upper limb
dexterity, and articulation speed, respectively [41]. In the
former, the time will be recorded that it takes for a partici-
pant to walk a distance of 8m as quickly as possible but
safely. In the 9HPT, subjects are asked to fill the nine
holes of the peg hole board with pegs one at a time as
quickly as possible and then, without pausing, to remove
them again one at a time. Lastly, in the PATA repetition
rate task subjects repeat the “PATA” phrase as quickly as
possible for ten seconds. The number of PATA repeats
will then be counted.
Transcranial magnetic stimulation
The inhibitory influence of the cerebellum on the
contralateral primary motor cortex (M1), a physio-
logical phenomenon called cerebellar brain inhibition
(CBI), can be evaluated using a dual-coil TMS para-
digm. CBI can be demonstrated by a reduction of the
motor evoked potential (MEP) amplitude when a test
stimulus over M1 is preceded by a conditioning
stimulus administered over the contralateral cerebellar
hemisphere with an interval of 5 to 7 ms [42]. In pa-
tients with cerebellar ataxia due to lesions in the
cerebellar efferent pathway, CBI is either significantly
reduced or absent [43–45].
The CBI paradigm will be applied at T0 and T1. Con-
ditioning stimuli will be delivered to the posterior and
superior lobules of the right cerebellar hemisphere at a
point 1 cm below and 3 cm lateral to the inion on the
line joining the external auditory meatus. Although both
double-cone coils and figure-of-eight coils have been
previously utilized for this purpose, a recent systematic
review concluded that the majority of CBI studies ar-
gued for the former [46]. Because the double-cone coil
generates a larger electromagnetic field as compared to
the conventional figure-of-eight coils and is therefore
able to reach deeper target tissues, we also decided to
use this coil (Magstim 110mm) in the administration of
cerebellar conditioning stimuli. Indeed, Hardwick and
colleagues could not elicit CBI using the figure-of-eight
coil in healthy young individuals, even at intensities of
65–80% maximum stimulator output, whereas CBI was
readily present at all intensities when using the double-
cone coil [47]. The coil will be oriented such that an up-
ward brain current is achieved. A Magstim 70mm
figure-of-eight coil will be used to excite the hand repre-
sentation of the left primary motor cortex with the
handle pointed 45° posterolaterally to the midsagittal
plane. MEPs are registered from the first dorsal interos-
seus muscle of the right hand through Kendall H69P
surface electrodes in a belly-tendon montage.
After localizing and marking the motor hotspot on the
tight-fitting cap worn by the participant (in order to
guarantee a constant optimal coil position throughout
the experiment), the resting motor threshold (rMT) will
be assessed. The latter is defined as the lowest stimula-
tor output to elicit MEPs (≥ 50 μV or visible by contrac-
tion) in five out of ten trials during muscle relaxation.
The intensity of the cerebellar conditioning stimuli is set
at 90% rMT of the contralateral M1 [29, 31, 48–51],
while the intensity of motor cortex test pulses will be ad-
justed to produce MEPs with peak-to-peak amplitudes
of 0.5–1.0 mV. Although it is true that the studies that
delivered cerebellar conditioning stimuli at an intensity
of 90% rMT obtained from M1 made use of a figure-of-
eight coil, it can be assumed that a similar and more re-
liable effect can be accomplished by a double-cone coil.
Twenty trials will be conducted for each interstimulus
interval (3 ms, 5 ms, 10 ms, and test pulse only) and pre-
sented in a pseudorandomized sequence. The ratio be-
tween the mean MEP amplitude after application of the
dual-coil paradigm and the test stimulus will be calcu-
lated for each interstimulus interval.
Delay eyeblink classical conditioning
Delay eyeblink classical conditioning refers to a motor
learning paradigm, which is dependent on the structural
and functional integrity of cerebellar circuits [52]. In
healthy individuals repeated time-locked coupling of an
auditory tone (conditioned stimulus, CS) and a supra-
orbital nerve stimulus or corneal air puff (unconditioned
stimulus, US) ultimately leads to the presence of a con-
ditioned eyeblink (conditioned response, CR) prior to
the US. Patients with degenerative cerebellar disorders
and focal cerebellar lesions have been reported to show
significantly diminished acquisition of CRs and no reten-
tion when multiple eyeblink conditioning sessions are
applied [53–55]. Notably, the acquisition process already
seems to be disturbed during the preclinical stage of
SCA3 [33, 56].
In this study, we aim to investigate whether dimin-
ished acquisition of CRs in SCA3 patients is a static
trait, which we postulated before, or whether this
process could be enhanced by a two-week treatment
with cerebellar anodal tDCS. To this end, we will apply
a validated protocol previously described by Teo and
colleagues and also used in our own study on preclinical
SCA3 mutation carriers [56, 57]. Patients will be com-
fortably seated in a chair, having their back turned to the
computer screen so they cannot see when the CS and
US are presented. The US consists of an electrical
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stimulus (250 V, 200 μs duration) generated by a Digiti-
mer DS7A that stimulates the right supraorbital nerve
through a pair of Kendall H69P electrodes. The cathode
is placed in the supraorbicular fossa, the anode 2 cm
above the cathode. The stimulus level will be determined
individually by multiplying the sensory threshold inten-
sity by a factor 7 to 10. Two pairs of Kendall H69P elec-
trodes will be used to record the electromyographic
activity from both orbicularis oculi muscles. The active
and reference electrodes will be placed just caudal to the
lower eyelids and 2–3 cm from the lateral canthi, re-
spectively. The CS consists of a loud auditory tone, pre-
sented via binaural headphones, and precedes the US by
400 ms, eventually co-terminating with it.
The conditioning protocol comprises six blocks of
eleven trials: trials 1–9 are CS-US-paired, trial 10 is CS-
only, and trial 11 is US-only. Trial 10 is inserted to ensure
that acquisition of CRs occurs independent of the US. Ex-
tinction will be tested for by including a seventh block of
eleven CS-only trials. Using this protocol, the percentage
and timing of acquired conditioned responses will be
assessed as well as the occurrence of extinction.
Static posturography
Static posturography will be performed to provide a
quantitative, kinetic measure of standing balance per-
formance compared to the more descriptive SARA
stance item. To this end, subjects are asked to stand
barefoot on a 60 × 40 cm force plate (Motekforce Link),
which measures the excursion of the center of pressure
(CoP) in the anteroposterior and mediolateral directions
at a sampling rate of 1000 Hz. For each participant the
“optimal” intermalleolar distance will be determined, de-
fined as the smallest distance between the left and right
medial malleolus in steps of 5 cm at which a subject
stands comfortably without a tendency to fall. This value
will be used throughout the study. Fixed lines are ap-
plied to the force plate to facilitate these measurements.
Participants are instructed to look straight ahead at a
fixed target at the wall with their arms relaxed along
their body and stand as quietly as possible during three
trials of 30 s each with pauses in between. The investiga-
tor will stand next to the subject for safety reasons.
Cerebellar transcranial direct current stimulation
Cerebellar tDCS will be delivered by two 7 × 5 cm rubber
electrodes, which are connected to a neuroConn con-
stant current stimulator. Similar to the set-up applied by
Benussi and colleagues [29], the anode – encased in a
dampened sponge envelope – will be placed in the mid-
line 2 cm below the inion in order to reach both cerebel-
lar hemispheres, while the cathode is attached to the
skin overlying the right deltoid muscle. The anode and
cathode are coated with electroconductive gel and paste,
respectively, to maintain impedance levels below 5 kΩ
throughout the stimulation. Elastic gauzes and tape are
used to ensure fixation of the electrodes.
Following a ramp-up time of 30 s, as recommended
previously to ensure proper blinding and reduce side ef-
fects [58], in which the current intensity is gradually in-
creased from 0 to 2 mA, a maintenance current of 2 mA
will be delivered for 20 min in case of real cerebellar
stimulation (0.057 mA/cm2). Hereafter, the current is
gradually decreased to 0 mA again during a fade-out
period of 30 s. In sham sessions, the duration of real
stimulation by convention is 40 s (i.e., 1200 / 30), dir-
ectly preceded and followed by 30 s of ramp-up and
ramp-down. The remainder of the time (i.e., 1160 s) con-
sists of continuous impedance control without any
stimulation. This is accomplished by the occurrence of a
small current pulse every 550ms (110 μA over 15 ms,
peak current duration 3 ms) that enables reliable detec-
tion of bad electrode contact or disconnection. Both
conditions will thus be indistinguishable with respect to
electrode set-up, session duration, and physical sensa-
tions. After two weeks of stimulation, patients are asked
to which group they think they were allocated.
Participants may experience mild itching, prickling, or
burning sensations underneath the electrodes that dis-
appear after a while. Considering the extensive exclusion
criteria, the screening procedure, and constant monitoring
of the subjects, we do not expect serious adverse events.
The risks of tDCS are considered negligible. No serious
adverse events have been reported [23, 59] and the similar
stimulation protocol used by the Italian group yielded no
side effects [29]. In any case, the investigator will make
sure that the stimulation is fully tolerable at the beginning
as well as throughout the experiment. Measurements will
be terminated whenever the participant does not tolerate
the measurement or whenever the investigator believes it
is not safe to proceed.
Outcome measures
The various outcome measures are listed in Table 2.
Statistical analysis
Statistical analyses will be conducted using SPSS and, in
general, the significance level is set at p < 0.05. Where ap-
propriate, we will use either chi-square tests, t-tests, or
two-way ANOVAs with TIME as within-subject factor
(number of levels depending on the specific outcome
measure, ranging from two to five) and TREATMENT as
between-subject factor (anodal tDCS versus sham tDCS).
Subsequently, Bonferroni-corrected post-hoc testing is
performed to explore significant main effects. Possible
correlations with functional scores will be addressed using
Spearman’s rank-order correlations.
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This study is exploratory in nature. In the previ-
ously conducted Benussi et al. trial, the authors in-
cluded 20 patients with a variety of ataxias and were
able to demonstrate significant differences between
the stimulation and sham groups in SARA, ICARS,
8MWT, and 9HPT [29]. In the current study, the
same sample size of 20 SCA3 patients is chosen (n =
10 real stimulation, n = 10 sham stimulation). Based
on the data presented in the aforementioned study, a
calculation (G*Power 3) revealed a power of 83% to
detect significant differences when using SARA as the
primary outcome measure (effect size 0.46, α = 0.05,
sample size 20).
Discussion
n this randomized, double-blind, sham-controlled trial
the effects of a two-week regimen with daily sessions of
cerebellar anodal tDCS will be evaluated for the first
time in SCA3 patients. Since patients with less severe
ataxia tended to have the largest decrease in coordin-
ation deficits in a previous pilot study [29], which likely
suggests that the volume of viable cerebellar cortex that
can be stimulated plays a crucial role, we will include
mildly to moderately affected individuals. Although it is
the main aim of this trial to investigate the effects of
cerebellar tDCS on ataxia severity, a variety of other out-
come measures will be used that reflect the spectrum of
deficits observed in patients with cerebellar diseases
such as SCA3. In fact, ours is the first study in patients
with ataxia that also examines the effects of cerebellar
tDCS on non-motor parameters. Relating to the
clinically-oriented nature of the study, the outcome mea-
sures are mainly administered at the outpatient clinic. In
addition, a paired-pulse TMS paradigm will be applied
to investigate whether the physiological phenomenon of
cerebellar brain inhibition – known to be reduced or ab-
sent in patients with lesions in the cerebellar efferent
pathway – returns after repeated tDCS sessions.
While the focus will be on the immediate post-
treatment (T1) versus baseline differences, we plan to
have a follow-up of up to one year. It is very import-
ant to determine the exact time curve of the effect (if
any) in order to establish the repeat frequency of the
intervention to design implementation protocols. Fur-
thermore, we will investigate whether transient effects
on motor outcomes are already elicited by a single
session of tDCS. In this respect, the SARA score and
performances on the 8MWT, 9HPT, PATA repetition
rate, and static posturography at T0 will all be com-
pleted within 30 to 45 min after the end of the cere-
bellar tDCS, which falls well within the estimated time
window of after-effects of a single tDCS bout [60].
Notwithstanding the exponentially increasing use of
cerebellar tDCS in both healthy individuals and (the
promising results in) patients with various neurological
disorders, its underlying mechanism of action has not
been entirely clarified. Unlike TMS, which makes use of
the principle of electromagnetic induction to directly
elicit neuronal depolarization, the weak currents in an-
odal tDCS are thought to modulate the excitability of
the neuronal membrane potential rather than instantan-
eously evoke action potentials. In this regard, anodal
stimulation leads to a shift in the membrane potential
towards depolarization, conditional on the degree of
alignment between a neuronal membrane and the elec-
tric field, while the opposite is true for cathodal stimula-
tion [58]. The situation for cerebellar tDCS, however, is
more difficult to predict than with cerebral stimulation
given the specific cytoarchitecture and complex gyration
pattern of the former. As stressed previously, repeated
sessions of anodal tDCS may induce long-lasting (plasti-
city) effects, which might result from a change in ionic
gradients in the extracellular space, augmentation of
synapses, modulation of certain receptors and neuro-
transmitters, redistribution of membrane proteins, in-
duction of specific cellular processes, and/or increased
cerebellar perfusion [23, 58].
If we can demonstrate that cerebellar stimulation via
anodal tDCS improves ataxia and perhaps non-motor
features in SCA3 patients, this would mean that there is
a readily available, safe, and affordable tool for its man-
agement in the neurorehabilitation setting. Furthermore,
positive effects will stimulate further research into this
intervention in other SCAs and heredodegenerative
ataxias for which effective treatment options are cur-
rently lacking. Finally, the observation that extended, re-
motely supervised at-home tDCS treatment has proven
feasible in cerebellar ataxia may facilitate future clinical
implementation once the efficacy of this technique has
been established on a larger scale [61].
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